Teva Launches First Generic Versions of HIV-1 Treatments TRUVADA® (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) and ATRIPLA® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) Tablets in the U.S.
TEL AVIV & PARSIPPANY, N.J.–(BUSINESS WIRE)–Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva…
ComplianceQuest and Zolon PCS Selected to Modernize U.S. Food and Drug Administration (FDA) Enterprise Quality Management System
Stagwell Launches New Global Media Agency, Stagwell Media
TMX Group Consolidated Trading Statistics – September 2026
eBRAM Launches the 5th Accredited Professional Mediation Training Course
U.S. Polo Assn. Celebrates an Outstanding 2026 European Polo Season